Pancreatic targeting of IL-22 therapy for diabetes [ 2016 - 2018 ]

Research Grant

Researchers: Prof Michael Mcguckin (Principal investigator) ,  Dr Sumaira Hasnain ,  Prof Johannes Prins ,  Prof Ross Barnard

Brief description Type 2 diabetes is one of the largest problems facing health care and presents an enormous therapeutic market. Our approach with IL-22 fights the disease at the core of the problem in the pancreatic ?-cells that make insulin. Our patent focuses on targeting IL-22 to the ?-cells which promises to maximise therapeutic benefits while minimising potential adverse effects in other tissues. Independently, and in collaboration with Novo Nordisk, we are making prototype drugs to achieve this.

Funding Amount $AUD 495,436.86

Funding Scheme Development Grants

Notes Development Grant